Phaseline

Companies › Vividion Therapeutics

Vividion Therapeutics: clinical trials, targets and expected readouts

3 active drug programs in 4 registered trials: 3 Phase 1, 1 Phase 2; Oncology; next expected readout May 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
VVD-133214
WRN protein inhibitor
WRNPhase 2Colorectal Adenocarcinoma; Advanced Solid TumorsMay 2027
VVD-159642
RAS-PI3Kα inhibitor
KRAS, PIK3CAPhase 1Advanced Solid TumorsAug 2027
VVD-130037–Phase 1Advanced Solid TumorsAug 2030

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06004245VVD-133214Phase 1Advanced Solid TumorsOncologyMay 2027
NCT06804824VVD-159642Phase 1Advanced Solid TumorsOncologyAug 2027
NCT07811193VVD-133214Phase 2Colorectal AdenocarcinomaOncologyJun 2028
NCT05954312VVD-130037Phase 1Advanced Solid TumorsOncologyAug 2030

Targets

WRN (1) KRAS (1) PIK3CA (1)

Companies with the same targets

Eli Lilly Revolution Medicines TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) Roche Novartis Quanta Therapeutics Bristol-Myers Squibb Amgen Astellas Abbisko Therapeutics

Companies built like this

Kumquat Biosciences Genfleet Therapeutics (Shanghai) Eikon Therapeutics iOnctura Erasca

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.